Menu Search
Equities

Pharvaris NV

PHVS:NSQ

Pharvaris NV

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)22.61
  • Today's Change0.29 / 1.30%
  • Shares traded23.35k
  • 1 Year change+31.45%
  • Beta-3.1641
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy4
Outperform3
Hold0
Sell1
Strong Sell0

Share price forecast in EUR

The 8 analysts offering 12 month price targets for Pharvaris NV have a median target of 32.47, with a high estimate of 49.96 and a low estimate of 13.99. The median estimate represents a 43.59% increase from the last price of 22.61.
High121.0%49.96
Med43.6%32.47
Low-38.1%13.99

Earnings history & estimates in EUR

On Aug 14, 2024, Pharvaris NV reported 2nd quarter 2024 losses of -0.55 per share. This result was in line with the consensus of the 6 analysts following the company and exceeded last year's 2nd quarter results by 12.70%.
The next earnings announcement is expected on Nov 20, 2024.
Average growth rate+0.68%
Pharvaris NV reported annual 2023 losses of -2.63 per share on Apr 10, 2024.
Average growth rate-1.37%
More ▼

Revenue history & estimates in EUR

Pharvaris NV did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Pharvaris NV did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.